search
Back to results

REnAL denervatIon by ultraSound Transcatheter Emission (REALISE)

Primary Purpose

Resistant Hypertension

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
PARADISE percutaneous renal denervation
Sponsored by
ReCor Medical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Resistant Hypertension focused on measuring Hypertension, Blood pressure, Renal denervation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Resistant hypertension, as defined in the 2007 ESH-ESC guidelines
  • 18 years of age or older
  • Negative pregnancy test for female patients of childbearing potential
  • Willing and able to comply with follow-up requirements
  • Signed informed consent

Exclusion Criteria:

  • Secondary hypertension
  • Main renal arteries length < 20 mm
  • Main renal arteries diameter < 4 mm
  • Renal artery stenosis
  • Iliac/femoral artery stenosis precluding insertion of the catheter
  • Allergy to contrast media
  • Currently participating in the study of an investigational drug or device
  • Hemodynamics abnormality
  • Moderate to severe renal insufficiency

Sites / Locations

  • Université de Toulouse et CHU
  • Hôpital Pitié-Salpêtrière

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Percutaneous renal denervation

Arm Description

Outcomes

Primary Outcome Measures

Percentage of successful interventions
A successful intervention is defined by the ability to successfully: Introduce the PRDS catheter Position the PRDS catheter Deliver ultrasound energy Retrieve the PRDS catheter
Percentage of patients with device- or procedure-related adverse events
Anticipated adverse events include: Puncture site-related events Renal artery stenosis, aneurysm, dissection, or perforation Renal infarction, acute kidney injury, or renal failure Arterial and venous thromboembolic events (including myocardial infarction, stroke, aortic or peripheral artery disease, etc.)

Secondary Outcome Measures

Change from baseline in ambulatory blood pressure
Change from baseline in anti-hypertensive medication intake

Full Information

First Posted
January 19, 2012
Last Updated
July 5, 2018
Sponsor
ReCor Medical, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01529372
Brief Title
REnAL denervatIon by ultraSound Transcatheter Emission
Acronym
REALISE
Official Title
REnAL denervatIon by ultraSound Transcatheter Emission
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ReCor Medical, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The REALISE trial is a single-arm, open-label, prospective, post market evaluation to be conducted on twenty (20) eligible patients with a twelve month follow-up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resistant Hypertension
Keywords
Hypertension, Blood pressure, Renal denervation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Percutaneous renal denervation
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
PARADISE percutaneous renal denervation
Other Intervention Name(s)
ReCor Medical PARADISE
Intervention Description
Intravascular ultrasound emission
Primary Outcome Measure Information:
Title
Percentage of successful interventions
Description
A successful intervention is defined by the ability to successfully: Introduce the PRDS catheter Position the PRDS catheter Deliver ultrasound energy Retrieve the PRDS catheter
Time Frame
Up to 24 hours
Title
Percentage of patients with device- or procedure-related adverse events
Description
Anticipated adverse events include: Puncture site-related events Renal artery stenosis, aneurysm, dissection, or perforation Renal infarction, acute kidney injury, or renal failure Arterial and venous thromboembolic events (including myocardial infarction, stroke, aortic or peripheral artery disease, etc.)
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change from baseline in ambulatory blood pressure
Time Frame
12 months
Title
Change from baseline in anti-hypertensive medication intake
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Resistant hypertension, as defined in the 2007 ESH-ESC guidelines 18 years of age or older Negative pregnancy test for female patients of childbearing potential Willing and able to comply with follow-up requirements Signed informed consent Exclusion Criteria: Secondary hypertension Main renal arteries length < 20 mm Main renal arteries diameter < 4 mm Renal artery stenosis Iliac/femoral artery stenosis precluding insertion of the catheter Allergy to contrast media Currently participating in the study of an investigational drug or device Hemodynamics abnormality Moderate to severe renal insufficiency
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles Montalescot, Professor
Organizational Affiliation
Hôpital Pitié-Salpêtrière
Official's Role
Principal Investigator
Facility Information:
Facility Name
Université de Toulouse et CHU
City
Toulouse
ZIP/Postal Code
1048
Country
France
Facility Name
Hôpital Pitié-Salpêtrière
City
Paris
State/Province
Île-de-France
ZIP/Postal Code
75013
Country
France

12. IPD Sharing Statement

Learn more about this trial

REnAL denervatIon by ultraSound Transcatheter Emission

We'll reach out to this number within 24 hrs